Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (26616)	11/18/1998 2:47:00 PM
From: Cheryl Galt	Read Replies (1) \| Respond to of 32384

>>I find it very sad that the FDA panel would choose to "eyeball" pictures << Likewise. How unscientific! Good thing Boeing technicians use better criteria for evaluating bonds, and material strength and integrity. (Mostly NON-invasive techniques too.) There must be OBJECTIVE techniques for evaluating wounds, better than both pictures AND individual doctor's testimony. At the very least, carefully tabulated measurements, made with proper tools. I'd like to find out the criteria the FDA used to evaluate Allergan's Tazorac Gel (tazarotene) in June 1997 and Roche's Soriatane (acitretin) in October 1996. Ligand ought to be able to study those proceedings, and learn from the earlier experience. The FDA ought to be consistent in their requirements, and make those requirements known from the start. Were they known from the start? Regards, Cheryl